Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02LPY
|
|||
| Former ID |
DNCL001696
|
|||
| Drug Name |
A-623
|
|||
| Synonyms |
ZINC48553401
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Systemic lupus erythematosus [ICD-11: 4A40.0; ICD-9: 710] | Phase 2/3 | [1] | |
| Company |
Anthera Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C16H15N3OS2
|
|||
| Canonical SMILES |
CC1=C(SC(=N1)NC(=S)N)C(=O)C=CC=CC2=CC=CC=C2
|
|||
| InChI |
1S/C16H15N3OS2/c1-11-14(22-16(18-11)19-15(17)21)13(20)10-6-5-9-12-7-3-2-4-8-12/h2-10H,1H3,(H3,17,18,19,21)/b9-5+,10-6+
|
|||
| InChIKey |
BOEHSSIGBYYFMA-NXZHAISVSA-N
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01609452) MONICA-SC: A Study to Evaluate the Efficacy, Safety and Tolerability of Blisibimod (A-623) Administration in Subjects With ITP. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.